Mingyue Optical Lens Co., Ltd. Class A

Mingyue Optical Lens Co., Ltd. Class A

SSZSE:301101
37.71
CNY
-0.11
(-0.29%)
1.14EPS
27.26P/E
6.03BMarket Cap
Apr 28Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.37
3.83
3.8
3.57
3.81
3.09
3.72
3.84
4.12
4.64
Basic EPS, GAAP
0.13
0.25
0.48
0.46
0.54
0.68
0.78
0.88
0.96
1.1
Free Cash Flow per Basic Share
0.15
0.45
0.41
0.42
0.74
0.34
0.63
0.7
0.93
- -
Dividend per Share
0.03
0.37
0.22
- -
- -
0.35
0.2
0.3
0.51
0.5
Book Value per Share
1.74
1.85
3
3.49
6.97
7.29
7.72
8.28
8.75
9.14
Tangible Book Value per Share
1.46
1.57
2.72
3.2
6.76
7.09
7.53
8.06
8.52
8.85
Basic Weighted Avg Shares
126
133
146
151
151
202
202
201
201
201
Sales/Revenue/Turnover
426
509
553
540
576
623
749
770
828
931
Operating Margin (%)
9.32
13.58
19.39
18.62
18.66
22.51
23.35
24.5
25.34
26.38
Depreciation Expense
24
24
20
22
28
28
35
43
48
- -
Net Income, GAAP
17
33
70
70
82
136
158
177
193
220
Effective Tax Rate (%)
24.33
18.14
16.64
16.07
14.65
9.77
14.1
13.74
12.8
13.28
Profit Margin (%)
3.95
6.45
12.64
12.97
14.26
21.86
21.04
22.95
23.31
23.65
Working Capital
59
96
268
342
1,233
1,230
1,304
1,404
1,460
1,480
LT Debt
- -
- -
- -
4
- -
6
3
1
2
- -
Total Equity
281
300
481
563
1,445
1,512
1,604
1,716
1,804
1,874
Return on Invested Capital (%)
- -
13.84
24.72
18.86
9.65
9.77
11.06
11.32
11.46
12.46
Return on Capital (%)
- -
12.7
15.55
11.1
7.2
8.45
9.11
9.96
10.25
11.69
Return on Common Equity (%)
- -
12.08
19.03
14.27
8.5
9.48
10.41
10.96
11.24
12.56

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
46
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
202
202
202
Market Capitalization
6,652
5,489
6,025

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,720
1,617
1,699
Cash, Cash Equivalents & STI
1,354
1,273
1,315
Accounts Receivable, Net
200
161
186
Inventories
92
104
99
Total Current Liabilities
219
180
219
Payables & Accruals
- -
- -
- -
ST Debt
46
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
35.87%
5.08%
Free Cash Flow
- -
32.76%
32.51%
Net Income, GAAP
- -
24.04%
9.13%
Sales/Revenue/Turnover
- -
9.08%
7.43%
Total Cash Common Dividend
- -
- -
68.36%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
192
193
198
187
770
2025
197
202
- -
201
828
2026
233
223
273
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.23
0.24
0.2
0.88
2025
0.23
0.24
- -
0.22
0.96
2026
0.28
0.27
0.33
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.3
2025
- -
0.5
- -
- -
0.51
2026
- -
0.57
-0.07
- -
- -

Company Description

CEO
Gong Xing Xie
Full Time Employees
1,066
Sector
Health technology
Industry
Medical specialties
Address
Shanghai China
IPO Date
Dec 16, 2021
Business
Mingyue Optical Lens Co., Ltd. is a China-based optical lens manufacturer engaged in the research, development, design, production, and distribution of optical resin lenses, raw lens materials, and related eyewear products. Founded in 2002 and tracing its manufacturing origins to 1997, the company is headquartered in Shanghai, China, maintains its primary manufacturing and industrial base in Danyang, Jiangsu Province, and operates an international regional center in Singapore to support overseas market expansion. The company operates through a vertically integrated business model spanning upstream chemical monomer synthesis, specialized lens casting and coating, and downstream frame design and finished eyewear assembly. The company provides a comprehensive portfolio of optical products and services, categorized into: functional and corrective optical lenses, including adolescent myopia management lenses marketed under the EasyGo and EasyGo Pro series utilizing multi-point defocus ocular axis control technology; ultra-high and high-refractive-index lenses, encompassing 1.60, 1.67, 1.71, and 1.74 index product lines; progressive multifocal lenses for presbyopia correction; anti-fatigue and digital eye-strain relief lenses; blue-light filtering, photochromic, and polarized outdoor sunglass lenses; specialized post-operative and protective lenses; and customized prescription optics; raw optical materials and chemical resin monomers, encompassing proprietary KR resin, KR ultra-tough impact-resistant resin, and PMC ultra-bright high-transmittance resin delivering light transmittance rates up to 98.6 percent; and eyewear accessories and assembly solutions, including optical frames, sunglass frames, precision lens edging, optical laboratory processing, and one-stop prescription eyewear fulfillment services for optical retailers, optometrists, and medical ophthalmology clinics. In recent developments, Mingyue Optical Lens has executed significant product innovations, commercial partnerships, and strategic expansions across the vision care and wearable technology markets. The company introduced its 1+4+N product strategy to prioritize growth in high-refractive-index 1.74 series lenses, PMC ultra-bright optics, progressive multifocal lenses, and outdoor tinted categories, underscored by the commercial rollout of the EasyGo Light Advantage myopia management lens featuring intelligent contrast calibration technology. In smart hardware, the company established a commercial supply partnership with Xiaomi for optical lenses integrated into smart audio glasses, while actively exploring collaborative development with additional consumer electronics firms in the smart eyewear and augmented reality segments. To deepen its clinical presence, Mingyue Optical Lens expanded collaborative clinical trials and distribution agreements with specialized ophthalmic institutions, including Zhongshan Ophthalmic Center and Aier Eye Hospital Group. Furthermore, the company broadened brand engagement through cross-industry intellectual property licensing partnerships with Universal Pictures, completed a board of directors governance transition in late 2025, and established strategic upstream monomer reserves and alternative sourcing initiatives to secure manufacturing operations against raw material market volatility.